Keywords
Hodgkin Disease
Epidemiology
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the profile of patients with Hodgkin's Lymphoma refractory to first-line treatment. Methods: This is a cross-sectional, retrospective analytical study with secondary data and a quantitative and descriptive approach, attended at reference hospital in amazonia, with patients with HL who were refractory or relapsed after undergoing first-line treatment. Results: 48 patients with a mean age of 30-39 years, with a time of diagnosis between 2 and 5 years in 68.75%, predominance in the nodular sclerosis subtype of 70.84% were evaluated. B symptoms were present in 91.67% and Bulky disease in 50% at diagnosis. Bone marrow transplantation was performed in 29% of the patients, 12.5% died, remaining patients were in remission or following some type of treatment. Conclusion: HL is a highly curable disease, but refractoriness continues to occur in a number of cases, which can be better managed with access to specific medications and the existence of a transplant center in the state.
References
BRAY F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin., 2018; 68(6): 394-424.
EICHENAUER DA, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood, 2018; 132(14): 1519–1525.
EICHENAUER DA e ENGERT A. How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Blood, 2020; 136(26): 2987-2993.
HERNÁNDEZ-RAMÍREZ RU, et al. Cancer risk in HIV-infected people in the USA from 1996 to 2012: A population-based, registry-linkage study. Lancet HIV, 2017; 4: e495-e504.
HOPPE RT, et al. Hodgkin Lymphoma, Version 2.2020. J Natl Compr Canc Netw., 2020; 18(6): 755-781.
HUANG J, et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. Journal of Hematology & Oncology, 2022; 15: 57.
HUTCHINGS M, et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica, 2006; 91: 482–489.
INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA (INCA). Estimativa 2020: incidência de câncer no Brasil / Instituto Nacional de Câncer. – Rio de Janeiro: INCA, 2020.
KELLER SP, et al. Late Relapses Following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin Lymphoma (HL) in the ABVD Therapeutic era. Biol Blood Marrow Transplant, 2012; 18(4): 640-647.
MOHTY R, et al. Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies. Blood Cancer Journal, 2021; 11: 126.
MOMOTOW J. et al. Hodgkin Lymphoma-Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients. J. Clin. Med., 2021; 10: 1125.
MONTEIRO TAF, et al. Linfoma de Hodgkin: aspectos epidemiológicos e subtipos diagnosticados em um hospital de referência no Estado do Pará, Brasil. Rev Pan-Amaz Saude, 2016; 7: 1.
MOTOK A e STEILD C. Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood, 2018; 131: 15.
RIBEIRO LA, et al. Linfoma de Hodgkin: Análise de desfechos em óbito no Brasil, na região Norte e no Amapá em uma década. Research, Society and Development, 2021; 10(1).
ROSE A, et al. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes from a 28-Year Single Institutional Experience. Clin Lymphoma Myeloma Leuk., 2021; 21(2): 132-138.
SHAH GJ e MOSKOWITS CH. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood, 2018; 131(15): 1689-1687.
SHANBHAG S e AMBINDER RF. Hodgkin Lymphoma: A Review and Update on Recent Progress. CA CANCER J CLIN., 2018; 68: 116–132.
STRAUS DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol, 2021; 8(6): e410-e421.
VASSILAKOPOULOS TP, et al. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. Ther Adv Hematol., 2020; 11: 1–31.
WANG H, et al. Diagnosis of Hodgkin lymphoma in the modern era. British Journal of Haematology, 2019; 184: 45–59.
WENIGER MA e KÜPPERS R. Molecular biology of Hodgkin lymphoma. Leukemia, 2021; 35: 968–981.